A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors.
Adolescent
Age Factors
Antineoplastic Agents
/ adverse effects
Cancer Survivors
/ statistics & numerical data
Cohort Studies
Female
Gastric Mucosa
/ drug effects
Humans
Intestinal Mucosa
/ drug effects
Intestinal Polyposis
/ epidemiology
Male
Neoplasms
/ mortality
Radiotherapy
/ adverse effects
Stomach Diseases
/ epidemiology
Young Adult
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
04
09
2019
revised:
10
12
2019
accepted:
09
01
2020
pubmed:
14
2
2020
medline:
30
3
2021
entrez:
14
2
2020
Statut:
ppublish
Résumé
Prior small reports have postulated a link between gastrointestinal polyposis and childhood and young adulthood cancer (CYAC) treatment (therapy-associated polyposis; TAP), but this remains a poorly understood phenomenon. The aim of this study was to describe the phenotypic spectrum of TAP in a multi-institutional cohort. TAP cases were identified from eight high-risk cancer centers. Cases were defined as patients with ≥10 gastrointestinal polyps without known causative germline alteration or hereditary colorectal cancer predisposition syndrome who had a history of prior treatment with chemotherapy and/or radiotherapy for CYAC. A total of 34 TAP cases were included (original CYAC: 27 Hodgkin lymphoma, three neuroblastoma, one acute myeloid leukemia, one medulloblastoma, one nephroblastoma, and one non-Hodgkin lymphoma). Gastrointestinal polyposis was first detected at a median of 27 years (interquartile range, 20-33) after CYAC treatment. A total of 12 of 34 (35%) TAP cases had ≥50 colorectal polyps. A total of 32 of 34 (94%) had >1 histologic polyp type. A total of 25 of 34 (74%) had clinical features suggestive of ≥1 colorectal cancer predisposition syndrome [e.g., attenuated familial adenomatous polyposis (FAP), serrated polyposis syndrome, extracolonic manifestations of FAP, mismatch repair-deficient colorectal cancer, or hamartomatous polyposis] including 8 of 34 (24%) with features of multiple such syndromes. TAP is an apparently acquired phenomenon that should be considered in patients who develop significant polyposis without known causative germline alteration but who have had prior treatment for a CYAC. Patients with TAP have features that may mimic various hereditary colorectal cancer syndromes, suggesting multiple concurrent biologic mechanisms, and recognition of this diagnosis may have implications for cancer risk and screening.
Identifiants
pubmed: 32051178
pii: 1940-6207.CAPR-19-0416
doi: 10.1158/1940-6207.CAPR-19-0416
pmc: PMC7060102
mid: NIHMS1550107
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-298Subventions
Organisme : NCI NIH HHS
ID : K07 CA151769
Pays : United States
Organisme : NCI NIH HHS
ID : K24 CA113433
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA132829
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Future Oncol. 2010 Apr;6(4):539-49
pubmed: 20373868
Science. 1993 May 7;260(5109):816-9
pubmed: 8484122
Clin Gastroenterol Hepatol. 2014 Jun;12(6):1046-50
pubmed: 24362051
Dig Dis Sci. 2018 Sep;63(9):2451-2455
pubmed: 29855768
Gut. 2017 Sep;66(9):1645-1656
pubmed: 27329244
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Cancer Med. 2019 Jan;8(1):190-199
pubmed: 30592184
J Natl Cancer Inst. 2018 Jul 1;110(7):758-767
pubmed: 29986097
BMC Cancer. 2016 Nov 8;16(1):862
pubmed: 27821077
Am J Clin Pathol. 2007 Jun;127(6):938-45
pubmed: 17509991
Lancet. 1978 Feb 4;1(8058):245-7
pubmed: 74668
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985
Science. 1993 May 7;260(5109):812-6
pubmed: 8484121
J Pathol. 1996 May;179(1):20-5
pubmed: 8691339
Cell. 1996 Oct 18;87(2):159-70
pubmed: 8861899
J Clin Oncol. 2015 Jan 10;33(2):209-17
pubmed: 25452455
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1778-84
pubmed: 17035382
Eur J Hum Genet. 2018 Mar;26(3):387-395
pubmed: 29367705
Lancet Oncol. 2012 Jun;13(6):598-606
pubmed: 22552011
Cancer. 2019 Mar 15;125(6):990-999
pubmed: 30561773
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
JAMA. 2011 Jun 8;305(22):2311-9
pubmed: 21642683
Nature. 1992 Sep 17;359(6392):235-7
pubmed: 1528264
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1308-12
pubmed: 23660415
Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5
pubmed: 18237868
J Clin Oncol. 2018 Jul 20;36(21):2145-2152
pubmed: 29874133
Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263
pubmed: 25645574
Clin Gastroenterol Hepatol. 2013 Jun;11(6):705-11; quiz e46
pubmed: 23376323
Ann Intern Med. 2012 Jun 5;156(11):757-66, W-260
pubmed: 22665813
Gut. 2017 Oct;66(10):1797-1801
pubmed: 27411369
J Clin Oncol. 2012 Jul 10;30(20):2552-8
pubmed: 22665546